Sana CFO Wyrick exercises 7,500 RSUs, sells shares

Sana Biotechnology, Inc. officer Susan D. Wyrick, identified as Acting Chief Financial Officer and Principal Accounting Officer, reported equity transactions involving company stock.

Rhea-AI Filing Summary

Sana Biotechnology, Inc. officer Susan D. Wyrick, identified as Acting Chief Financial Officer and Principal Accounting Officer, reported equity transactions involving company stock. On January 2, 2026, 7,500 restricted stock units were converted to common stock at $0.00 per share, reflecting previously granted compensation that vested 40% on January 2, 2025 and 60% on January 2, 2026. The corresponding RSU award balance went to zero after this conversion.

On January 5, 2026, Wyrick reported a transaction coded "F" involving 2,407 shares of common stock at $4.27 per share, after which she directly held 185,883 shares of Sana Biotechnology common stock.

Insider Trade Summary

7,500 shares exercised/converted

Exercise 3 txns

Insider Wyrick Susan D.

Role See Remarks

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	2,407	$4.27	$10K
Exercise	Restricted Stock Units	7,500	$0.00	$0.00
Exercise	Common Stock	7,500	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 0 contracts (Direct); Common Stock — 185,883 shares (Direct)

Footnotes (2)

1. F1. Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. common stock.
2. F2. The award vested as to 40% of the restricted stock units on January 2, 2025 and 60% of the restricted stock units on January 2, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who is the insider in this Sana Biotechnology (SANA) Form 4 filing?

The insider is Susan D. Wyrick, who serves as Sana Biotechnology, Inc.'s Acting Chief Financial Officer and Principal Accounting Officer.

What RSU activity did Susan Wyrick report at Sana Biotechnology (SANA)?

On January 2, 2026, Susan Wyrick reported the conversion (code "M") of 7,500 restricted stock units into an equal number of Sana Biotechnology common shares at $0.00 per share.

How did the restricted stock units vest for Susan Wyrick at Sana Biotechnology (SANA)?

The filing states that the RSU award vested as to 40% of the units on January 2, 2025 and 60% on January 2, 2026, with each unit representing one share of common stock.

What stock sale or disposition did Susan Wyrick report for Sana Biotechnology (SANA)?

On January 5, 2026, Susan Wyrick reported a transaction coded "F" involving 2,407 shares of Sana Biotechnology common stock at a price of $4.27 per share.

How many Sana Biotechnology shares does Susan Wyrick own after these transactions?

Following the reported transactions, Susan Wyrick directly beneficially owned 185,883 shares of Sana Biotechnology, Inc. common stock.

What does each restricted stock unit represent in this Sana Biotechnology (SANA) filing?

The filing explains that each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/06/2026 - 04:18 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wyrick Susan D.

(Last) (First) (Middle)

C/O SANA BIOTECHNOLOGY, INC.

188 EAST BLAINE STREET, SUITE 400

(Street)

SEATTLE WA 98102

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Sana Biotechnology, Inc. [ SANA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/02/2026		M		7,500	A	$0.00	188,290	D
Common Stock	01/05/2026		F		2,407	D	$4.27	185,883	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	01/02/2026		M			7,500	(2)	(2)	Common Stock	7,500	(1)	0.00	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. common stock.

2. The award vested as to 40% of the restricted stock units on January 2, 2025 and 60% of the restricted stock units on January 2, 2026.

Remarks:

Acting Chief Financial Officer and Principal Accounting Officer

	/s/ Aaron M. Grossman, Attorney-in-Fact for Susan D. Wyrick	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.